email   Email Us: info@lupinepublishers.com phone   Call Us: +1 (914) 407-6109   57 West 57th Street, 3rd floor, New York - NY 10019, USA

Lupine Publishers Group

Lupine Publishers

ISSN: 2644-1217

Open Access Journal of Complementary & Alternative Medicine

Case ReportOpen Access

Modulating Serum Lipids with Berberine in Naturopathic Clinical Practice Volume 3 - Issue 5

Wayne Reilly*

    Wellness Care, Australia

Received: November 01, 2021   Published: November 19, 2021

*Corresponding author: Wayne Reilly, Wellness Care Australia Pty Ltd, 61 Holsworthy St Coorparoo Qld Australia

DOI: 10.32474/OAJCAM.2021.03.000171

Fulltext PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Medical intervention to reduce the risk of atherosclerosis using lipid modulating medications has been a target for reducing cardiovascular risk for over 40 years. Lipid lowering medications, HMG-CoA reductase inhibitors (Statin’s), and more recently PCSK9 inhibitors (PCSK9i (protein convertase subtilisin/kexin type 9 inhibitors) are now and in the future will be the main stay therapy for reducing Atherosclerosis. However, the uncertainty of statin induced myalgia and other bad publicity via the media and internet reports has caused many patients to opt out of statin therapy. Berberine and is quinoline alkaloid has had several clinical trials demonstrating potential in managing cardiovascular disease risk. Berberine is a safe and natural alternative for modulating circulating lipids including LDL-C, however possible drug interactions, due to its effects on P450 enzymes, does indicate some caution should be exercised.

Abstract| Introduction| Berberine In Cardiovascular Therapy| Conclusion| References |

Close

Online Submission System

Drag and drop files here

or

Browse Files
( For multiple files submission, zip them in a single file to submit. For file zipping software Download )